Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL3755773 | 0.90 | — | — | |
| Acetonitrile SCHEMBL28350050 | 0.90 | APLNR (0.32) | — | |
| Acetonitrile SCHEMBL1832586 | 0.90 | — | — | |
| Acetic Acid SCHEMBL28642946 | 0.88 | FFAR3 (0.39) | — | |
| Acetic Acid SCHEMBL27768086 | 0.88 | FFAR3 (0.39) | — | |
| Acetone SCHEMBL27655476 | 0.88 | TSHR (0.38) | LMNA | |
| Acetonitrile SCHEMBL7316992 | 0.87 | — | — | |
| Acetonitrile SCHEMBL522737 | 0.87 | — | — | |
| Acetonitrile SCHEMBL16267560 | 0.87 | APLNR (0.33) | — | |
| Acetonitrile SCHEMBL9936942 | 0.87 | APLNR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140127160-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664273-B2 | Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-8431615-B2 | Dose forms | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| EP-1910341-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120045415-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2402331-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2256113-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20060105978-A1 | Dose forms | VERTEX PHARMACEUTICALS INCORPORATED | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105978-A1 | Dose forms | HAVCR2, CCL5, ZC3HAV1 | LMNA 2637/4885 |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | LMNA 1400/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | LMNA 1400/4885 |
| US-20120045415-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | IFNAR1, IFNG, EIF2AK2 | LMNA 3075/4885 |
| US-20140127160-A1 | TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN | IFNAR1, IFNG, EIF2AK2 | LMNA 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.